Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute
pulmonary embolism, either symptomatic or not. The occlusion of proximal pulmonary arteries …

… Conflict of interest: E. Grünig reports grants and personal fees from Actelion and Bayer/MSD,
grants from GSK, and personal fees from Bial, OrPhaSwiss GmbH and Medscape, outside …

Major discoveries have been obtained within the last decade in the field of hereditary
predisposition to pulmonary arterial hypertension (PAH). Among them, the identification of bone …

Background Data on the effect of initial combination therapy with ambrisentan and tadalafil
on long-term outcomes in patients with pulmonary arterial hypertension are scarce. Methods …

Background Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase
2 trial to be beneficial in the treatment of pulmonary arterial hypertension. Methods In this …

Objective Earlier detection of pulmonary arterial hypertension (PAH), a leading cause of death
in systemic sclerosis (SSc), facilitates earlier treatment. The objective of this study was to …

Background— Pulmonary hypertension (PH) is associated with restricted physical capacity,
limited quality of life, and a poor prognosis because of right heart failure. The present study …

Background Pulmonary arterial hypertension is a progressive disease involving proliferative
remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-…

Background— By its inhibitory effect on platelet-derived growth factor signaling, imatinib
could be efficacious in treating patients with pulmonary arterial hypertension (PAH). Methods …

The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification
strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-…